BELACT® · PHARMACEUTICAL DEVELOPMENT PROGRAM
From D016 technology to a controlled pharmaceutical development pathway.
BELACT is Pharmact’s lead pharmaceutical development program built around D016. HoFH is the planned lead orphan-development indication. BELACT remains investigational and is not an approved medicinal product.
Development-stage representation · not a clinical-status claim
PROGRAM POSITION
BELACT translates D016 into a separately controlled medicinal-product development pathway. Pharmaceutical development is governed by its own CMC, nonclinical, clinical and regulatory requirements.
Recombinant hyaluronidase technology and the technical foundation of the BELACT program.
Homozygous familial hypercholesterolemia is the current planned orphan-development focus.
Direct exploratory preclinical evidence is available; clinical BELACT evidence is not yet established.
BfArM interactions inform development planning. They do not constitute approval, authorization or orphan designation.
HOW THE PROGRAM EVOLVED
BELACT did not begin as a finished clinical proposition. The program evolved through scientific context, recombinant technology development, direct D016 preclinical work and regulatory-development discussion.
External mechanistic work and historical observations contributed to the scientific rationale around hyaluronan-degrading enzymes and vascular extracellular-matrix biology. These sources are context, not D016 efficacy evidence.
Recombinant D016 established a controlled biotechnology asset with a designed PH20-like / HYAL4-like dual-activity profile that could be characterized, manufactured and developed under application-specific quality requirements.
An exploratory non-GLP LDLR−/− mouse study generated direct D016 preclinical evidence. The high-dose group was associated with a smaller aortic-root lesion area versus vehicle; this does not establish clinical efficacy.
VIEW VERIFIED CRL DATA →The documented interaction addressed nonclinical development, 14-day repeat-dose toxicology in two species, PK/TK considerations and an initial healthy-volunteer SAD/MAD dose-finding approach before patient studies.
CURRENT DEVELOPMENT POSITION
ESTABLISHED / AVAILABLE
IN DEVELOPMENT / NOT YET ESTABLISHED
PLANNED LEAD INDICATION
Pharmact currently prioritizes homozygous familial hypercholesterolemia as the planned lead orphan-development indication for BELACT.
Strategic indication priority is not the same as clinical study order. “Orphan-first” describes Pharmact’s indication-development strategy. It does not mean that HoFH patients would necessarily be the first human participants.
The documented 2021 BfArM Scientific Advice recommended initial dose finding in healthy volunteers using SAD/MAD, followed by adult/adolescent patient work before pediatric HoFH. Future protocol sequencing remains subject to nonclinical data, CMC readiness and updated regulatory advice.
FUTURE DEVELOPMENT PATH
Each stage is intended to reduce a defined development risk before the program advances. The sequence is a planning framework, not a promise of clinical outcome, timing or authorization.
Demonstrate pharmaceutical manufacturing reproducibility, expand analytical/CMC documentation, complete the required short-term repeat-dose toxicology program and address PK/TK.
Decision: clinical-entry readinessSubject to regulatory alignment and an adequate enabling package, initiate controlled dose finding in healthy volunteers using SAD/MAD to characterize safety, tolerability, dose and exposure.
Decision: patient-study readinessAdvance into suitable patient populations based on emerging data and regulatory advice. The exact sequence, endpoints and populations require protocol-specific regulatory alignment.
Decision: evidence for next-stage developmentDevelop the HoFH program and later-stage clinical strategy, including orphan-development planning, CMC/GMP supply and potential licensing or co-development pathways.
Decision: pivotal / partnering readiness as supported by dataDEVELOPMENT PRINCIPLE
BELACT DEVELOPMENT BOUNDARY
BELACT is an investigational pharmaceutical development program. No clinical safety or efficacy has been established for BELACT. Preclinical findings, historical observations and regulatory-development interactions do not constitute an authorization or orphan designation and do not establish clinical benefit.
BELACT DEVELOPMENT & PARTNERING
Scientific, development and partnering discussions are structured according to development stage, intended scope and applicable regulatory requirements.